In the ongoing phase 3, CheckMate 214 trial, nivolumab plus ipilimumab improved overall survival compared with sunitinib in patients with intermediate or poor risk, previously untreated, advanced renal cell carcinoma.

According to a study that was published by the Journal of Urology, a total of 112 tumors in 106 patients were treated with radio frequency ablation. The median followup was 79 months (IQR 28.9-121.1) and mean ± SD tumor size was 2.5 ± 0.8 cm. Initial technical success was achieved in 97 percent of cases.

Personalized treatment plans may extend life expectancy for early-stage kidney cancer patients who have risk factors for worsening kidney disease, according to a new study published in the journal Radiology.

VEGF TKIs have long defined the frontline standard of care in metastatic renal cell carcinoma (mRCC), but several promising trials evaluating their use in combination with immunotherapy agents may redefine the frontline setting in this patient population.

Yesterday, Bristol-Myers Squibb announced that the European Commission has approved the combination of Opdivo (nivolumab) 3 mg/kg plus Yervoy (ipilimumab) 1 mg/kg (“low-dose”) for the first-line treatment of patients with intermediate- and poor-risk advanced renal cell carcinoma (RCC).

Royal jelly, a substance secreted by worker honeybees that is the exclusive food for queen bees, may ease the adverse effects of tyrosine kinase inhibitor (TKI) therapy for advanced renal cell carcinoma (RCC).

A clinical trial in the U.K. has just launched to assess the effectiveness of a newly developed breath test that could help diagnose multiple forms of cancer, including kidney cancer.

The rate of people dying from cancer in the United States seems to have dropped steadily for 25 years, a new study says, but disparities remain between the rich and the poor. The overall nationwide cancer death rate fell continuously from 1991 to 2016 by a total of 27%, according to a study by the American Cancer Society, published Tuesday in CA: A Cancer Journal for Clinicians.

Looking to enroll in a clinical trial? Check out this list from the National Cancer Institute.